Menu Close

Congrats to Drs. Adrian V. Lee, Steffi Oesterreich, and Daniel D. Brown for their contributions to the latest Nature publication: A dependency map enhanced with next-generation 3D cancer models!

Congrats to Drs. Adrian V. Lee, Steffi Oesterreich, and Daniel D. Brown for their contributions to the latest Nature publication: A dependency map enhanced with next-generation 3D cancer models!
https://www.nature.com/articles/s41586-026-10843-7

This work was a collaboration with the Broad Institute of MIT and Harvard. Breast cancer patient-derived organoid (PDO) models were developed by Daniel Brown in the Institute for Precision Medicine in collaboration with the Lee-Oesterreich lab, and some of these PDO models were provided to the Broad Institute. The Broad team ran genome-scale CRISPR screens across 147 organoid and spheroid models spanning 10 cancer types, expanding the Cancer Dependency Map (DepMap) into tumor subtypes traditional cell lines simply don’t capture. These models preserve transcriptional programs that get silenced in 2D culture (like the PDAC-classical/MUC program in GI organoids), and oncogene dependency itself can be model-dependent. Model choice shapes the biology we’re able to see.

This manuscript was one of three companion papers published together in Nature, all validating patient-derived 3D cancer models as the next generation of preclinical tools.

Our contribution to this work was supported in part by NIH R01CA252378 through the National Cancer Institute (NCI) Oncology Models Forum, grateful for that support in helping make this collaboration possible.

This seminal paper is published alongside two outstanding companion papers:
Herranz-Ors et al. (Wellcome Sanger Institute), “A tumour-derived organoid biobank maps cancer gene dependencies” — 256 clinically annotated organoids across five GI/gynecologic cancers, with genome-wide CRISPR dependency screens on 162 of them.

ElHarouni et al., “A compendium of next-generation patient-derived models for diverse cancers” — the Human Cancer Models Initiative’s landmark 665-model resource across 25 cancer types.

Together, these three papers make a compelling, converging case that organoids and related New Approach Methodologies (NAMs) can faithfully recapitulate tumor biology at a scale sufficient for systematic target discovery, not just as a nice complement to cell lines, but as tools that reveal biology cell lines miss entirely. That’s the bet we’ve made with the Organoid Research Core here at Pitt, and it’s exciting to see it borne out across multiple independent efforts at once.

– A dependency map enhanced with next-generation 3D cancer models | Nature
– A tumour-derived organoid biobank maps cancer gene dependencies | Nature
– A compendium of next-generation patient-derived models for diverse cancers | Nature

Patient-Derived Organoid Workshop hosted by Dr. Adrian Lee and the Institute for Precision Medicine

The Institute for Precision Medicine hosted the NCI-BCRF-Komen workshop on “Patient-Derived Breast Cancer Organoids: Challenges & Opportunities” on May 21-22, 2025 at The Assembly in Pittsburgh, PA.

The meeting was co-organized by myself, Sandra Demaria, Ariella Hanker, and Senthil Muthuswamy.

We brought together 45 investigators to discuss the state-of-the-art in PDO research and gaps that present barriers to progress.

The lively event raised several excellent points about how PDOs are credentialed and used in research. In particular, their use in predicting patient response to therapy (e.g., co-clinical trials) was a hotly discussed topic.

The National Institutes of Health recently promoted organoid models to reduce the reliance on animal models, and we hope that these novel alternative metholodologies will provide new avenues for precision medicine.

We thank The Breast Cancer Research Foundation and Susan G. Komen for sponsoring the workshop and advocates Bob Riter and Jamie LaScala who participated in a panel discussion on obtaining tissue for research.

Outcomes and deliverables of the workshop will be a white paper on best practices in breast cancer PDO research and hopefully a new network that can share PDO and data and accelerate this research.

If you are interested in participating in the Breast Organoid Working Group (BOWG) contact Dr. Adrian Lee.

New Publication from Dr. Julia Foldi & the L/O Lab: personalized ctDNA in metastatic ILC

Julia Foldi MD and colleagues from the Lee-Oesterreich laboratory collaborated with Natera Inc to report on retrospective analysis of real-world data in 66 patients with metastatic ILC using a clinically validated, personalized, tumor-informed ctDNA assay (Signatera). Serial ctDNA testing in patients with mILC is feasible and may enable personalized surveillance and real-time therapeutic monitoring.

https://pubmed.ncbi.nlm.nih.gov/40324116

Pink Warriors Visit the Lee/Oesterreich Lab

Eight members of The Pink Warriors, the only breast cancer club at the University of Pittsburgh, joined the lab for a tour of the facilities, Wednesday night, February 7, 2024. They received a tour of the building from Dr. Lee and both Drs. Lee and Oesterreich spoke to them about breast cancer research and answered questions. Afterward they enjoyed a catered dinner. They learned a great deal from the lab tour and lab members were impressed with their questions. Contact information was exchanged and plans were laid for them to participate with the lab in the upcoming Rush to Crush Cancer and the Susan G. Komen More Than Pink Walk, both May 19, 2024.